Rizkallah Jacques, Sood Manish M, Reslerova Martina, Cordova Francisco, Malik Amrit, Sathianathan Chris, Estrella-Holder Estrellita, Zieroth Shelley
Clin Nephrol. 2013 Nov;80(5):334-41. doi: 10.5414/CN108038.
Peritoneal dialysis (PD) for long-term management of diuretic resistant volume overload in heart failure (HF) may provide potential benefit with few adverse consequences. We examined the impact of PD on clinical status hospitalizations, and complications of therapy in severe end-stage HF.
A consecutive case series of 10 transplant ineligible patients receiving PD solely for HF volume management between 2007 and 2011 was evaluated with clinical data reviewed pre- and post-PD initiation.
The mean ejection fraction (EF) pre-PD was 24.5 ± 6.0% with the majority of patients having NYHA class IIIB symptoms and moderate-severe right ventricular dysfunction. 9/10 patients were Stage 3 chronic kidney disease (CKD) or worse. After PD initiation, average weight loss was almost 7 kg (p = 0.016) with improvement in diuretic response, peripheral edema, and functional class. There was a significant decrease in re-hospitalization from an average of 3.2 ± 2.5 to 0.1 ± 0.3 admissions per patient (p = 0.007) and reduced average length of stay from 37 ± 36.7 to 0.78 ± 2.3 days (p = 0.019).
Objective criteriabased institution of PD for the treatment of diuretic refractory severe-end-stage HF was well tolerated and demonstrated favorable outcomes; these included improved clinical status, reduced hospitalizations and length of stay, with very few and easily treatable PDrelated complications. PD appears to be a viable option in refractory, end-stage congestive heart failure (CHF).
腹膜透析(PD)用于心力衰竭(HF)中对利尿剂抵抗的容量超负荷的长期管理可能带来潜在益处且不良反应较少。我们研究了PD对严重终末期HF患者临床状况、住院情况及治疗并发症的影响。
对2007年至2011年间连续收治的10例仅因HF容量管理而接受PD治疗且不符合移植条件的患者进行病例系列研究,回顾PD开始前后的临床资料进行评估。
PD开始前平均射血分数(EF)为24.5±6.0%,大多数患者有纽约心脏协会(NYHA)IIIB级症状和中度至重度右心室功能障碍。10例患者中有9例为3期慢性肾脏病(CKD)或更严重。PD开始后,平均体重减轻近7kg(p=0.016),利尿剂反应、外周水肿和心功能分级均有改善。再住院率显著降低,每位患者平均住院次数从3.2±2.5次降至0.1±0.3次(p=0.007),平均住院天数从37±36.7天降至0.78±2.3天(p=0.019)。
基于客观标准采用PD治疗利尿剂难治性严重终末期HF耐受性良好且疗效显著;这些疗效包括临床状况改善、住院次数和住院天数减少,且PD相关并发症极少且易于治疗。PD似乎是难治性终末期充血性心力衰竭(CHF)的一个可行选择。